文献速递神经肿瘤

大分割高能质子束照射是WHO I级脑膜瘤的一种替代治疗

Hypofractionated high-energy proton-beam irradiation is an alternative treatment for WHO grade I meningiomas.
PubMed 文献 · Acta Neurochir (Wien) · 2017-10-24

研究纳入1994至2007年接受质子照射的170例WHO I级脑膜瘤患者,多数位于颅底(155例),采用大分割方案(3-8次,通常每次5或6 Gy),平均剂量21.9 Gy(范围14-46 Gy),中位随访84个月。5年和10年无进展生存率分别为93%和85%,疾病特异性死亡率1.7%(3/170),放疗相关并发症16例(9.4%)。作者认为大分割质子束放疗尤其可用于无法全切的较大WHO I级脑膜瘤。

要点

  • 5年和10年无进展生存率分别为93%和85%,疾病特异性死亡率1.7%(3/170)。
  • 放疗相关并发症16例(9.4%),垂体功能不全最常见。
  • 前颅窝肿瘤是唯一显著增加并发症风险的因素。

核心结论

  • 大分割质子束放疗尤其可用于无法全切的较大WHO I级脑膜瘤,长期肿瘤控制率高且并发症风险可接受。

研究设计与样本

  • 研究纳入1994至2007年因WHO I级脑膜瘤接受质子照射的170例患者,多数肿瘤位于颅底(155例)。
  • 84例为次全切除术后辅助放疗,42例为肿瘤复发时放疗,44例为基于典型影像学诊断后 upfront 放疗。
  • 照射采用大分割方式(3-8次,通常每次5或6 Gy),平均剂量21.9 Gy(范围14-46 Gy),中位随访84个月。

主要发现

  • 5年和10年无进展生存率分别为93%和85%。
  • 总死亡率为13.5%,疾病特异性死亡率为1.7%(3/170例)。
  • 年龄较大患者及肿瘤位于中颅窝的患者肿瘤进展风险较低。
  • 放疗相关并发症见于16例(9.4%),以垂体功能不全最常见。
  • 前颅窝肿瘤位置是唯一显著增加并发症风险的因素。

临床怎么用

  • 作者认为,大分割质子束放疗尤其可用于无法全切的较大WHO I级脑膜瘤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiation treatment is commonly employed in the treatment of meningiomas. The aim of this study was to evaluate the effectiveness and safety of hypofractionated high-energy proton therapy as adjuvant or primary treatment for WHO grade I meningiomas. METHOD: A total of 170 patients who received irradiation with protons for grade I meningiomas between 1994 and 2007 were included in the study. The majority of the tumours were located at the skull base (n = 155). Eighty-four patients were treated post subtotal resection, 42 at tumour relapse and 44 with upfront radiotherapy after diagnosis based on the typical radiological image. Irradiation was given in a hypofractionated fashion (3-8 fractions, usually 5 or 6 Gy) with a mean dose of 21.9 Gy (range, 14-46 Gy). All patients were planned for follow-up with clinical controls and magnetic resonance imaging scans at 6 months and 1, 2, 3, 5, 7 and 10 years after treatment. The median follow-up time was 84 months. Age, gender, tumour location, Simpson resection grade and target volume were assessed as possible prognostic factors for post-irradiation tumour progression and radiation related complications. RESULTS: The actuarial 5- and 10-year progression-free survival rates were 93% and 85% respectively. Overall mortality rate was 13.5%, while disease-specific mortality was 1.7% (3/170 patients). Older patients and patients with tumours located in the middle cranial fossa had a lower risk for tumour progression. Radiation-related complications were seen in 16 patients (9.4%), with pituitary insufficiency being the most common. Tumour location in the anterior cranial fossa was the only factor that significantly increased the risk of complications. CONCLUSIONS: Hypofractionated proton-beam radiation therapy may be used particularly in the treatment of larger World Health Organisation grade I meningiomas not amenable to total surgical resection. Treatment is associated with high rates of long-term tumour growth control and acceptable risk for complications.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Vlachogiannis P, Gudjonsson O, Montelius A, et al. Hypofractionated high-energy proton-beam irradiation is an alternative treatment for WHO grade I meningiomas. Acta Neurochir (Wien). 2017. PMID: 29064038. doi:10.1007/s00701-017-3352-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。